|drug3987||oral polio vaccine + information Wiki||1.00|
There is one clinical trial.
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection against progression of the current outbreak of COVID-19 infection, and any future variants, strains, mutations of the causative SARS-CoV-2 virus as well as protection from any future currently unknown newly emergent novel viruses.
Description: vaccine events such as fever, rash, abnormal vital signsMeasure: frequency of vaccine events Time: day 0 to day 28
Description: measurement of Th1/Th2 balance, allo-specific Th1/CTL responseMeasure: Proportion of subjects with positive T-cell response Time: day 0 to 1 year
Description: ex-vivo challenge of blood samples with live virus including SARS-CoV-2, influenza A and BMeasure: Proportion of subjects able to suppress viral propagation Time: day 0 to 1 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports